Amphista Therapeutics announces three key strategic leadership appointments to drive transition of its Targeted Glue(TM) protein degraders into clinical development GlobeNewswire October 23, 2025 Appointments for SVP of Clinical Operations, VP of Translational Science, and Head of Project and Portfolio Management will strengthen Amphista's clinical development capabilities and accelerate its ambition to bring its innovative […]

TRIDENT, a dedicated stroke outcomes trial in patients with a history of intracerebral hemorrhage (ICH), demonstrates the potential advantages of intensive blood pressure treatment with low-dose triple combination therapyTRIDENT, a dedicate GlobeNewswire October 23, 2025 GMRx2 significantly reduced the risk of recurrent stroke when added to standard of care compared to placebo Trial results were

Marex Group Plc to Announce Third Quarter 2025 Earnings on November 6, 2025 GlobeNewswire October 23, 2025 NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) — Marex Group plc (NASDAQ: MRX) today announced that it will release its fiscal 2025 third quarter results before market open on Thursday, November 6, 2025. The earnings release and supplementary

EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025 GlobeNewswire October 23, 2025 EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025 Company to host conference call and webcast on Thursday, November 6th at 8:30am EST AUSTIN, Texas, October 23, 2025 — EDAP TMS SA (Nasdaq: EDAP) (“the Company”),

Aebi Schmidt Group Declares Quarterly Dividend of $0.025 per Share and Announces Third Quarter 2025 Earnings Call Date of November 13, 2025 GlobeNewswire October 23, 2025 FRAUENFELD, Switzerland, Oct. 23, 2025 (GLOBE NEWSWIRE) — Aebi Schmidt Group (NASDAQ: AEBI) (“Aebi Schmidt” or the “Company”), a world-class specialty vehicles leader, today announced that its Board of

Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers GlobeNewswire October 23, 2025 – 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% – – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – –

INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025 GlobeNewswire October 23, 2025 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 23, 2025 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB) (the “Company”), INmune

HPQ Completes Latest Fumed Silica Pilot Test, Moves Closer to Achieving Highest Material Grades GlobeNewswire October 23, 2025 MONTREAL, Oct. 23, 2025 (GLOBE NEWSWIRE) — HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), a technology company driving innovation in advanced materials and critical process development, announces the successful completion of

— Revenue up 7% driven by increases across all major categories — EPS $5.65 up 23%, Adjusted EPS $5.01 up 25% — After-Sales gross profit of $597 million up 7% and gross margin of 48.7% (up 100bps) — Record CFS gross profit of $375 million up 12% — Strong cash flow and balanced capital deployments

GoBolt recognized among Canada's fastest-growing technology companies for the fifth consecutive year GoBolt, a technology company building the world's largest sustainable supply chain network, today announced it ranked No. 13 on the Enterprise – Industry Leaders award list as part of Deloitte's 2025 Technology Fast 50™ program. The annual awards recognize Canada's fastest-growing technology, media,